Cortical gray matter progression in idiopathic REM sleep behavior disorder and its relation to cognitive decline.

Brain Cognitive Dysfunction / diagnostic imaging Gray Matter / diagnostic imaging Humans Magnetic Resonance Imaging REM Sleep Behavior Disorder / diagnostic imaging
Cortical thickness IRBD Longitudinal data Olfactory dysfunction Parkinson’s disease Visuospatial functions

Journal

NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070

Informations de publication

Date de publication:
2020
Historique:
received: 10 05 2020
revised: 04 09 2020
accepted: 06 09 2020
pubmed: 22 9 2020
medline: 29 6 2021
entrez: 21 9 2020
Statut: ppublish

Résumé

Idiopathic Rapid eye movement sleep behavior disorder (IRBD) is recognized as the prodromal stage of the alpha-Synucleinopathies. Although some studies have addressed the characterization of brain structure in IRBD, little is known about its progression. The present work aims at further characterizing gray matter progression throughout IRBD relative to normal aging and investigating how these changes are associated with cognitive decline. Fourteen patients with polysomnography-confirmed IRBD and 18 age-matched healthy controls (HC) underwent neuropsychological, olfactory, motor, and T1-weighted MRI evaluation at baseline and follow-up. We compared the evolution of cortical thickness (CTh), subcortical volumes, smell, motor and cognitive performance in IRBD and HC after a mean of 1.6 years. FreeSurfer was used for CTh and volumetry preprocessing and analyses. The symmetrized percent of change (SPC) of the CTh was correlated with the SPC of motor and neuropsychological performance. IRBD and HC differed significantly in the cortical thinning progression in regions encompassing bilateral superior parietal and precuneus, the right cuneus, the left occipital pole and lateral orbitofrontal gyri (FWE corrected, p < 0.05). The Visual form discrimination test showed worse progression in the IRBD relative to HC, that was associated with gray matter loss in the right superior parietal and the left precuneus. Increasing motor signs in IRBD were related to cortical thinning mainly involving frontal regions, and late-onset IRBD was associated with cortical thinning involving posterior areas (FWE corrected, p < 0.05). Despite finding olfactory identification deficits in IRBD, results did not show decline over the disease course. Progression in IRBD patients is characterized by parieto-occipital and orbitofrontal thinning and visuospatial loss. The cognitive decline in IRBD is associated with degeneration in parietal regions.

Sections du résumé

BACKGROUND
Idiopathic Rapid eye movement sleep behavior disorder (IRBD) is recognized as the prodromal stage of the alpha-Synucleinopathies. Although some studies have addressed the characterization of brain structure in IRBD, little is known about its progression.
OBJECTIVE
The present work aims at further characterizing gray matter progression throughout IRBD relative to normal aging and investigating how these changes are associated with cognitive decline.
METHODS
Fourteen patients with polysomnography-confirmed IRBD and 18 age-matched healthy controls (HC) underwent neuropsychological, olfactory, motor, and T1-weighted MRI evaluation at baseline and follow-up. We compared the evolution of cortical thickness (CTh), subcortical volumes, smell, motor and cognitive performance in IRBD and HC after a mean of 1.6 years. FreeSurfer was used for CTh and volumetry preprocessing and analyses. The symmetrized percent of change (SPC) of the CTh was correlated with the SPC of motor and neuropsychological performance.
RESULTS
IRBD and HC differed significantly in the cortical thinning progression in regions encompassing bilateral superior parietal and precuneus, the right cuneus, the left occipital pole and lateral orbitofrontal gyri (FWE corrected, p < 0.05). The Visual form discrimination test showed worse progression in the IRBD relative to HC, that was associated with gray matter loss in the right superior parietal and the left precuneus. Increasing motor signs in IRBD were related to cortical thinning mainly involving frontal regions, and late-onset IRBD was associated with cortical thinning involving posterior areas (FWE corrected, p < 0.05). Despite finding olfactory identification deficits in IRBD, results did not show decline over the disease course.
CONCLUSION
Progression in IRBD patients is characterized by parieto-occipital and orbitofrontal thinning and visuospatial loss. The cognitive decline in IRBD is associated with degeneration in parietal regions.

Identifiants

DOI: 10.1016/j.nicl.2020.102421 PMID: 32957013 PMC: PMC7509231
pubmed: 32957013
pii: S2213-1582(20)30258-8
doi: 10.1016/j.nicl.2020.102421
pmc: PMC7509231
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102421

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Parkinsonism Relat Disord. 2012 Feb;18(2):136-9
pubmed: 21924943
Neurology. 2004 Jan 13;62(1):41-5
pubmed: 14718695
Neuroimage Clin. 2017 Aug 02;16:313-318
pubmed: 28856094
J Clin Neurol. 2019 Apr;15(2):175-183
pubmed: 30877691
Neurology. 2016 Apr 12;86(15):1400-1407
pubmed: 26865518
Neuroimage. 2011 Jul 1;57(1):19-21
pubmed: 21376812
Mov Disord. 2009 Jun 15;24(8):1193-9
pubmed: 19412935
Neurology. 2008 Apr 8;70(15):1250-7
pubmed: 18216303
Mov Disord. 2014 Oct;29(12):1495-503
pubmed: 25100674
J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):890-6
pubmed: 26361986
Mov Disord. 2006 Sep;21(9):1483-7
pubmed: 16705661
Sleep. 2013 Dec 01;36(12):1885-92
pubmed: 24293763
J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9
pubmed: 1627973
Brain. 2006 Mar;129(Pt 3):729-35
pubmed: 16401618
Sleep. 2011 May 01;34(5):619-25
pubmed: 21532955
Mov Disord. 2007 Dec;22(16):2314-24
pubmed: 18098298
Lancet Neurol. 2006 Jul;5(7):572-7
pubmed: 16781987
Neurology. 2014 Feb 18;82(7):620-7
pubmed: 24453082
Parkinsonism Relat Disord. 2018 Jan;46:62-68
pubmed: 29132765
Ann Neurol. 2009 Jul;66(1):39-47
pubmed: 19670440
Eur J Neurosci. 2009 Sep;30(6):1162-71
pubmed: 19735293
Front Neurol. 2019 Apr 05;10:312
pubmed: 31024418
Eur J Neurol. 2007 Jul;14(7):750-6
pubmed: 17594330
Brain. 2016 Aug;139(Pt 8):2224-34
pubmed: 27297241
Mov Disord. 2015 Apr 15;30(5):680-7
pubmed: 24676967
Brain. 2016 Apr;139(Pt 4):1180-8
pubmed: 26920675
Sleep Breath. 2019 Jun;23(2):587-593
pubmed: 30315394
Ann Neurol. 2011 Feb;69(2):400-7
pubmed: 21387382
Sleep Med. 2020 May;69:198-203
pubmed: 32135454
Cereb Cortex. 2018 Feb 1;28(2):658-671
pubmed: 28591814
Ann N Y Acad Sci. 2010 Jan;1184:15-54
pubmed: 20146689
Neurodegeneration. 1995 Mar;4(1):93-7
pubmed: 7600189
Mov Disord. 2010 Sep 15;25(12):1888-94
pubmed: 20669268
Parkinsonism Relat Disord. 2013 Jun;19(6):600-4
pubmed: 23529022
J Parkinsons Dis. 2019;9(4):723-731
pubmed: 31498130
Neuroimage Clin. 2020;25:102138
pubmed: 31911344
Acta Neurol Scand. 1995 Dec;92(6):455-63
pubmed: 8750110
Parkinsonism Relat Disord. 2014 Dec;20(12):1405-10
pubmed: 25457818
Sleep. 2013 Oct 01;36(10):1527-32
pubmed: 24082312
Neurology. 2018 May 15;90(20):e1759-e1770
pubmed: 29669906
Parkinsonism Relat Disord. 2019 Aug;65:197-202
pubmed: 31253493
J Int Neuropsychol Soc. 2018 Jan;24(1):33-44
pubmed: 28714429
Parkinsonism Relat Disord. 2019 Jul;64:286-292
pubmed: 31103485
Lancet Neurol. 2010 Nov;9(11):1070-7
pubmed: 20846908
Sleep. 2012 May 01;35(5):667-73
pubmed: 22547893
Parkinsonism Relat Disord. 2017 Aug;41:44-50
pubmed: 28522171
Sleep. 2010 Jun;33(6):767-73
pubmed: 20550017
Sleep. 2017 Nov 1;40(11):
pubmed: 28958075
Parkinsonism Relat Disord. 2010 Dec;16(10):645-9
pubmed: 20846895
NPJ Parkinsons Dis. 2019 May 3;5:7
pubmed: 31069252
Neurology. 2009 Mar 31;72(13):1121-6
pubmed: 19020293
PLoS One. 2014 Jan 23;9(1):e86624
pubmed: 24466177
Neuroimage. 2010 Dec;53(4):1181-96
pubmed: 20637289
Mov Disord. 2012 Sep 1;27(10):1255-61
pubmed: 22791632
Neurology. 2012 Dec 11;79(24):2302-6
pubmed: 23115214
Arch Neurol. 2000 Apr;57(4):489-93
pubmed: 10768622
Mov Disord. 2016 May;31(5):699-708
pubmed: 27094093
Ann Neurol. 2016 Jun;79(6):1026-30
pubmed: 27016314
Mov Disord. 2011 Aug 1;26(9):1717-24
pubmed: 21542022
Brain. 2019 Mar 1;142(3):744-759
pubmed: 30789229
Ann Neurol. 2017 Sep;82(3):419-428
pubmed: 28833467

Auteurs

A Campabadal (A)

Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain; Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.

A Inguanzo (A)

Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain; Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.

B Segura (B)

Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain; Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED:CB06/05/0018-ISCIII), Barcelona, Spain.

M Serradell (M)

Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED:CB06/05/0018-ISCIII), Barcelona, Spain; Sleep Disorders Center, Neurology Service, Hospital Clínic, Barcelona, Catalonia, Spain.

A Abos (A)

Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain.

C Uribe (C)

Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain.

C Gaig (C)

Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED:CB06/05/0018-ISCIII), Barcelona, Spain; Sleep Disorders Center, Neurology Service, Hospital Clínic, Barcelona, Catalonia, Spain.

J Santamaria (J)

Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED:CB06/05/0018-ISCIII), Barcelona, Spain; Sleep Disorders Center, Neurology Service, Hospital Clínic, Barcelona, Catalonia, Spain.

Y Compta (Y)

Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED:CB06/05/0018-ISCIII), Barcelona, Spain; Parkinson's Disease & Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain.

N Bargallo (N)

Centre de Diagnòstic per la Imatge, Hospital Clínic, Barcelona, Catalonia, Spain.

C Junque (C)

Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain; Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED:CB06/05/0018-ISCIII), Barcelona, Spain. Electronic address: cjunque@ub.edu.

A Iranzo (A)

Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED:CB06/05/0018-ISCIII), Barcelona, Spain; Sleep Disorders Center, Neurology Service, Hospital Clínic, Barcelona, Catalonia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Cortical gray matter progression in idiopathic...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Cortical gray matter progression in idiopathic...
questionsmedicales.fr › Système nerveux › Système nerveux central › Moelle spinale › Substance grise › Cortical gray matter progression in idiopathic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cortical gray matter progression in idiopathic...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Cortical gray matter progression in idiopathic...
questionsmedicales.fr › Troubles mentaux › Troubles de la veille et du sommeil › Parasomnies › Parasomnies du sommeil paradoxal › Trouble du comportement en sommeil paradoxal › Cortical gray matter progression in idiopathic...